Reported about 2 months ago
Eli Lilly's Alzheimer's drug, donanemab, is expected to be blocked by the NHS as it is reported that NICE is likely to reject its use, following a similar fate for lecanemab. Both drugs, which have shown effectiveness in slowing disease progression, face scrutiny over their costs and potential side effects. The decision on donanemab has been delayed, with no comments from NHS or NICE.
Source: YAHOO